Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Majadahonda – page 106

3 275 clinical trials in Majadahonda, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Majadahonda at a glance
3 275
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 275 trials in Majadahonda

Open in trial search

Safety of autologous NK cells with IL‑15 and CD45RA‑negative T cells with NKG2D CAR in children, adolescents and young adults with high‑grade brain tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD45RA- T-CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR AGAINST NKG2-D TYPE II INTEGRAL MEMBRANE PROTEIN
  • Sponsor:Hospital Universitario La Paz

Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis: Phase 2/3 Open‑Label and Randomized Placebo‑Controlled Study

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Myocarditis+1

Not yet recruiting

Effect of Calcifediol Monohydrate on Myocardial Fibrosis in Patients with Acute Myocarditis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcifediol monohydrate
  • Sponsor:Spanish Society Of Cardiology

Endometrial cancer+6

Not yet recruiting

Phase 2 Study of Lirafugratinib in Patients with Previously Treated Unresectable Advanced Solid Tumors with FGFR2 Fusion (Excluding Cholangiocarcinoma)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lirafugratinib hydrochloride
  • Sponsor:Elevar Therapeutics Inc.

Pancreatic carcinoma

Not yet recruiting

Phase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Not yet recruiting

Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Ideaya Biosciences Inc.

Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:ION337
  • Sponsor:Ionis Pharmaceuticals Inc.

Non-small cell lung cancer

Not yet recruiting

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib
  • Sponsor:Nuvation Bio Inc.

Bronchiectasis

Not yet recruiting

A Study of SAR445399 in Adults Aged 18‑80 with Non‑cystic Fibrosis Bronchiectasis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Narcolepsy

Not yet recruiting

A Randomized Double‑Blind Placebo‑Controlled Study of TAK‑360 in Adults with Narcolepsy with Cataplexy (Type 1)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bronchiectasis

Not yet recruiting

Efficacy of colistimethate sodium and ciprofloxacin for eradicating primary Pseudomonas aeruginosa infection in adults with bronchiectasis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Majadahonda

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on ATTR amyloid cardiomyopathy, evaluating new therapeutic approaches for both hereditary and wild-type variants of this heart condition.

  • Heart Disease Management
  • Cardiac Function Assessment
  • Disease Markers Evaluation

Multiple trials testing novel compounds to improve patient outcomes and quality of life.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting urinary tract infections and various herpes virus strains, including studies on both prevention and treatment.

  • UTI Prevention
  • Herpes Zoster Protection
  • Immunotherapy Development

Focus on long-term efficacy and immune response in different age groups.

03 Oncology Studies

Advanced research in multiple cancer types, including prostate cancer, gastric cancer, and lymphomas, with emphasis on targeted therapies and combination treatments.

  • Metastatic Disease Treatment
  • Novel Drug Combinations
  • Immunotherapy Approaches

Investigating breakthrough treatments for various stages of cancer progression.

04 Neurological Disorders

Pioneering research in cerebral ischemic stroke and multiple sclerosis, evaluating innovative treatments to improve patient outcomes and disease management.

  • Stroke Treatment
  • Progressive MS Management
  • Functional Recovery

Focus on both acute interventions and long-term disease modification.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.